Results

Total Results: 1,758 records

Showing results for "lead".
Users also searched for: pdsa

461. Use of Observational Studies in Systematic Reviews of (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-observational-studies_methods.pdf
     June 01, 2010 - gaps with initial consideration of the review questions or after discussion with content experts, may lead … usually require assessment at the individual study level: their consideration a priori will not likely lead … should be considered within and across studies; these flaws potentially invalidate the results (e.g., lead

462. preoperative-testing-protocol-130514 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/preoperative-testing_research-protocol.pdf
     May 14, 2013 - • Aberrant test results may lead to cascade testing (either appropriate if the test result signals …  sickle  cell)   o Urinalysis   o Pregnancy  tests   o Chest  radiography   o 12-­‐lead

463. Routine Preoperative Testing: Comparative Effectiveness Review | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/preoperative-testing/research-protocol
     May 14, 2013 - Aberrant test results may lead to cascade testing (either appropriate if the test result signals a real … Hemoglobinopathy tests (e.g., sickle cell) Urinalysis Pregnancy tests Chest radiography 12-lead

464. Comparative Effectiveness of Non-Invasive Diagnostic Tests for Breast Abnormalities – An Update of a 2006 Report | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/breast-abnormalities-tests-update/research-protocol
     June 28, 2010 - The comments received on the Key Questions did not lead to revisions of the Key Questions. … Although we recognize that excluding non-English studies could lead to bias in some situations, we believe

465. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1312.pdf
     December 01, 2013 - #06 Developmental Delays ADHD, and Autism AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 06: Developmental Delays, ADHD, and Autism Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither…

466. S38 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s38.pdf
     October 01, 2007 - same intervention can enhance compliance, and conversely assignment to different interventions can lead

467. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-2007_executive.pdf
     January 01, 2007 - Two trials indicated that a combination treatment of two biologic DMARDs can lead to substantially higher

468. Observed Association Between Antidepressant Use and Pneumonia Risk Was Confounded by Comorbidity Measures (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antidepressants-seniors-pneumonia_research.pdf
     May 01, 2008 - This signal arose in the context of a systematic process to screen for iatrogenic factors that may lead

469. Microsoft Word - ehcrr#2toCSI.doc (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/atypical-antipsychotics-seniors-death_research.pdf
     August 01, 2007 - study population in age and race/ethnicity suggest that any failure to adjust for such covariates will lead … intention- to-treat because of the known potential for drug intolerance or treatment failure that may lead

470. PHARMACO-EPIDEMIOLOGIC METHODS FOR A STUDY OF (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antipsychotic-medicine-cardiovascular-elderly_research.pdf
     February 01, 2009 - Hypoperfusion has been shown to lead to microinfarcts in dementia patients and investigators have proposed … for any improvements in the prevention of cardiac or cerebrovascular events, which could otherwise lead

471. Template for Reports Developed (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-topic-nomination_methods.pdf
     November 01, 2012 - Development Team Topic nomination development is typically conducted by a small team consisting of a team lead … The team lead is often a doctorally- trained person with a strong epidemiology, health services research … A poorly defined PICO can lead to development of a topic that may miss important populations, lack … A vague PICO also presents scoping challenges and may lead to a review that is too inclusive or too

472. Local Therapies for Unresectable Primary Hepatocellular Carcinoma: Comparative Effectiveness Review | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/liver-cancer-therapy/research-protocol
     March 20, 2012 - This may in turn lead the way for the complete ablation of larger size tumors. 23 Direct comparisons

473. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings | Effective Health Care (EHC) Program
     effectivehealthcare.ahrq.gov/products/alcohol-misuse-drug-therapy/research-protocol
     April 26, 2013 - Current Page Topic Timeline Sep. 20, 2012 Topic Initiated Apr. 26, 2013 Research Protocol May. 13, 2014 Systematic Review Sep. 22, 2014 Disposition of Comments Report Oct. 18, 2017 Surveillance Report Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings Research Protocol Archived April 26, …

474. Alcohol-misuse-drug-therapy-140326 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_research-protocol.pdf
     January 27, 2012 - Alcohol-misuse-drug-therapy-140326 …

475. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/04_dementia_potential_high_impact_june_2012.pdf
     January 01, 2012 - DEMENTIA INCLUDING ALZHEIMER'S #04 AHRQ Healthcare Horizon Scanning System – Potential High Impact Interventions Report Priority Area 04: Dementia (Including Alzheimer’s Disease) Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Ro…

476. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/04_dementia_potential_high_impact_2012-12-10.pdf
     January 01, 2012 - DEMENTIA INCLUDING ALZHEIMER'S #04 AHRQ Healthcare Horizon Scanning System – Potential High-Impact Interventions Report Priority Area 04: Dementia (Including Alzheimer’s Disease) Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road R…

477. Liver-Cancer-Therapy Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/liver-cancer-therapy_research-protocol.pdf
     November 28, 2012 - This may in turn lead the way for the complete ablation of larger size tumors.23 Direct comparisons

478. Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings: Systematic Review Update (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/alcohol-pharma-final-protocol.pdf
     January 01, 2023 - unclear but acamprosate is thought to antagonize glutamatergic N-methyl-D-aspartate receptors and lead … An updated review could lead to increased and more effective dissemination and has the potential to

479. Arthritis and Nontraumatic Joint Disease (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/arthritis-horizon-scan-high-impact-1306.pdf
     June 01, 2013 - Cervical DDD occurs when progressive changes in the cervical vertebral discs lead to loss of disc height … This may lead to different outcomes among treatment centers. … MSCs are purported to lead to cartilage regeneration because of the secretion of growth factors by … outcomes: Multilevel DDD presents a significant unmet need for new treatment options because ACDF can lead … However, the mechanism by which these cells lead to cartilage generation is still unclear.33 MSCs may

480. Hepatitis-C Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/hepatitis-c_executive.pdf
     November 01, 2012 - neuropsychiatric and hematologic adverse effects.23 Such adverse effects can be difficult to tolerate and can lead … regimen recommended by the FDA for antiviral-naïve patients with cirrhosis (4 weeks of dual therapy lead-in … regimens, shorter fixed duration triple therapy boceprevir therapy, and boceprevir without dual therapy lead-in … virologic response Two trials of triple therapy with boceprevir for 48 weeks (4 weeks of dual therapy lead-in … regimens on clinical outcomes in randomized trials or cohort studies is a challenge due to the long lead